Patents by Inventor Konrad Honold

Konrad Honold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Production of human mutated proteins in human cells by means of homologous recombination
    Patent number: 6444441
    Abstract: The invention concerns a process for the production of muteins of eukaryotic polypeptides in eukaryotic cells by means of homologous recombination. The invention additionally concerns a process for the production of human cells which are suitable for the production of human mutated proteins. Finally the invention concerns the human cells produced by the process and mutated human proteins obtainable therefrom as well as pharmaceutical preparations which contain these muteins.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: September 3, 2002
    Assignee: Roche Diagnostics GmbH
    Inventors: Anne Stern, Konrad Honold
  • Preparation of erythropoietin by endogenous gene activation
    Publication number: 20020110913
    Abstract: The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.
    Type: Application
    Filed: November 2, 2001
    Publication date: August 15, 2002
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll
  • PRODUCTION OF HUMAN MUTATED PROTEINS IN HUMAN CELLS BY MEANS OF HOMOLOGOUS RECOMBINATION
    Publication number: 20020068318
    Abstract: The invention concerns a process for the production of muteins of eukaryotic polypeptides in eukaryotic cells by means of homologous recombination. The invention additionally concerns a process for the production of human cells which are suitable for the production of human mutated proteins. Finally the invention concerns the human cells produced by the process and mutated human proteins obtainable therefrom as well as pharmaceutical preparations which contain these muteins.
    Type: Application
    Filed: January 21, 2000
    Publication date: June 6, 2002
    Inventors: ANNE STERN, KONRAD HONOLD
  • Production of erythropoietin by endogenous gene activation
    Patent number: 6391633
    Abstract: The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO inhuman cells, and a method for the large technical production of EPO in human cells.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: May 21, 2002
    Assignee: Roche Diagnostics GmbH
    Inventors: Anne Stern, Michael Brandt, Konrad Honold, Johannes Auer, Hans Koll
  • Positive-negative selection for homologous recombination
    Patent number: 6284541
    Abstract: The invention concerns a method for the introduction of a foreign DNA into the genome of a target cell by homologous recombination as well as for the homologous recombination of suitable DNA constructs.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: September 4, 2001
    Assignee: Roche Diagnostics GmbH
    Inventors: Johannes Auer, Raimund Sprenger, Konrad Honold
  • Use of plasminogen activators to stimulate local bone growth
    Patent number: 5888967
    Abstract: Described herein is a method of promoting osteogenesis in a patient in need thereof by administering a plasminogen activator which activates the zymogen plasminogen by cleavage between arginine 506 and valine 561 to form the serine protease plasmin.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: March 30, 1999
    Assignee: Boehringer Mannheim GmbH
    Inventors: Konrad Honold, Lothar Kling, Kurt Lang, Ulrike Leser